Antipsychotic polypharmacy in schizophrenia: ‘Secret sauce or wild abandon?’

Peter F. Buckley

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The treatment of schizophrenia has paradoxically become increasingly complex with the greater availability and choice among antipsychotic medications. At the same time, there is still substantial unmet need, as confirmed by recent large pragmatic trials in schizophrenia, which provides the therapeutic context for antipsychotic polypharmacy. For patients and clinicians, then, the question of "why and when do I combine medications? is now very challenging. All available evidence suggests that antipsychotic polypharmacy is common in clinical practice. Additionally, it is a topic of enduring interest among clinicians who are always eager to understand the information contributing to key therapeutic strategies. This chapter will provide a current appraisal of the extant evidence-base that informs the daily decision making process that is the clinician's dilemma: how should I use antipsychotic polypharmacy to its best advantage in my practice? The chapter will also critically evaluate the extent to which polypharmacy truly impacts tolerability considerations in treating schizophrenia

Original languageEnglish (US)
Title of host publicationPolypharmacy in Psychiatry Practice Volume II: Use of Polypharmacy in the "real world"
PublisherSpringer Netherlands
Pages3-10
Number of pages8
ISBN (Print)9789400757998, 9789400757981
DOIs
StatePublished - Jan 1 2013

Fingerprint

Polypharmacy
Antipsychotic Agents
Schizophrenia
Pragmatic Clinical Trials
Decision Making
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Buckley, P. F. (2013). Antipsychotic polypharmacy in schizophrenia: ‘Secret sauce or wild abandon?’. In Polypharmacy in Psychiatry Practice Volume II: Use of Polypharmacy in the "real world" (pp. 3-10). Springer Netherlands. https://doi.org/10.1007/978-94-007-5799-8_1

Antipsychotic polypharmacy in schizophrenia : ‘Secret sauce or wild abandon?’. / Buckley, Peter F.

Polypharmacy in Psychiatry Practice Volume II: Use of Polypharmacy in the "real world". Springer Netherlands, 2013. p. 3-10.

Research output: Chapter in Book/Report/Conference proceedingChapter

Buckley, PF 2013, Antipsychotic polypharmacy in schizophrenia: ‘Secret sauce or wild abandon?’. in Polypharmacy in Psychiatry Practice Volume II: Use of Polypharmacy in the "real world". Springer Netherlands, pp. 3-10. https://doi.org/10.1007/978-94-007-5799-8_1
Buckley PF. Antipsychotic polypharmacy in schizophrenia: ‘Secret sauce or wild abandon?’. In Polypharmacy in Psychiatry Practice Volume II: Use of Polypharmacy in the "real world". Springer Netherlands. 2013. p. 3-10 https://doi.org/10.1007/978-94-007-5799-8_1
Buckley, Peter F. / Antipsychotic polypharmacy in schizophrenia : ‘Secret sauce or wild abandon?’. Polypharmacy in Psychiatry Practice Volume II: Use of Polypharmacy in the "real world". Springer Netherlands, 2013. pp. 3-10
@inbook{173ef589bfd34290a85ebf6328b65067,
title = "Antipsychotic polypharmacy in schizophrenia: ‘Secret sauce or wild abandon?’",
abstract = "The treatment of schizophrenia has paradoxically become increasingly complex with the greater availability and choice among antipsychotic medications. At the same time, there is still substantial unmet need, as confirmed by recent large pragmatic trials in schizophrenia, which provides the therapeutic context for antipsychotic polypharmacy. For patients and clinicians, then, the question of {"}why and when do I combine medications? is now very challenging. All available evidence suggests that antipsychotic polypharmacy is common in clinical practice. Additionally, it is a topic of enduring interest among clinicians who are always eager to understand the information contributing to key therapeutic strategies. This chapter will provide a current appraisal of the extant evidence-base that informs the daily decision making process that is the clinician's dilemma: how should I use antipsychotic polypharmacy to its best advantage in my practice? The chapter will also critically evaluate the extent to which polypharmacy truly impacts tolerability considerations in treating schizophrenia",
author = "Buckley, {Peter F.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-94-007-5799-8_1",
language = "English (US)",
isbn = "9789400757998",
pages = "3--10",
booktitle = "Polypharmacy in Psychiatry Practice Volume II: Use of Polypharmacy in the {"}real world{"}",
publisher = "Springer Netherlands",

}

TY - CHAP

T1 - Antipsychotic polypharmacy in schizophrenia

T2 - ‘Secret sauce or wild abandon?’

AU - Buckley, Peter F.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The treatment of schizophrenia has paradoxically become increasingly complex with the greater availability and choice among antipsychotic medications. At the same time, there is still substantial unmet need, as confirmed by recent large pragmatic trials in schizophrenia, which provides the therapeutic context for antipsychotic polypharmacy. For patients and clinicians, then, the question of "why and when do I combine medications? is now very challenging. All available evidence suggests that antipsychotic polypharmacy is common in clinical practice. Additionally, it is a topic of enduring interest among clinicians who are always eager to understand the information contributing to key therapeutic strategies. This chapter will provide a current appraisal of the extant evidence-base that informs the daily decision making process that is the clinician's dilemma: how should I use antipsychotic polypharmacy to its best advantage in my practice? The chapter will also critically evaluate the extent to which polypharmacy truly impacts tolerability considerations in treating schizophrenia

AB - The treatment of schizophrenia has paradoxically become increasingly complex with the greater availability and choice among antipsychotic medications. At the same time, there is still substantial unmet need, as confirmed by recent large pragmatic trials in schizophrenia, which provides the therapeutic context for antipsychotic polypharmacy. For patients and clinicians, then, the question of "why and when do I combine medications? is now very challenging. All available evidence suggests that antipsychotic polypharmacy is common in clinical practice. Additionally, it is a topic of enduring interest among clinicians who are always eager to understand the information contributing to key therapeutic strategies. This chapter will provide a current appraisal of the extant evidence-base that informs the daily decision making process that is the clinician's dilemma: how should I use antipsychotic polypharmacy to its best advantage in my practice? The chapter will also critically evaluate the extent to which polypharmacy truly impacts tolerability considerations in treating schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84938263704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938263704&partnerID=8YFLogxK

U2 - 10.1007/978-94-007-5799-8_1

DO - 10.1007/978-94-007-5799-8_1

M3 - Chapter

AN - SCOPUS:84938263704

SN - 9789400757998

SN - 9789400757981

SP - 3

EP - 10

BT - Polypharmacy in Psychiatry Practice Volume II: Use of Polypharmacy in the "real world"

PB - Springer Netherlands

ER -